An integrated neuroscience company, Neurovision Imaging LLC is structured aroung delivery of scientifically validated diagnostic tests & biomarkers for early detection and monitoring of neurologic and ophthalmic disorders. With access to unique datasets, the firm offers data aggregation services, analysis, biostatistics, and applications of machine learning algorithms to large repositories of images and other biomarker data seeking to advance the collective understanding and prediction capabilities for neurodegenerative diseases. The firm is addressing a significant unmet need: cost-effective, noninvasive testing that can be applied to large segments of the at-risk population for preclinical Alzheimerâs Disease (AD) and AD dementia. NeuroVision is pursuing two initiatives to address this unmet need. (1) identification and direct measurement of amyloid-β protein (Aβ) plaques, the characteristic of AD pathology, in the retina of live human test subjects consisting of heathy controls, MCI and AD, versus amyloid PET and the gold-standard postmortem evaluation of amyloid in the brain. (2) fluid biomarkers using a platform that offers ultra-high sensitivity, multiplex capability and matrix insensitivity. Management seek also to leverage the firm's retinal image analysis expertise to develop and to commercialize tools to aid eye care professionals in the early identification of vision-threatening retinal disease and diseases that manifest in the reti
